Three Questions for Biotech
Executive Summary
When the market returns to steady-state, following its current valuation gyrations, we'd like to see biotechs answer three basic questions. Who will be the new financiers of the biotech industry--investors or pharma? How will biotechs show they can increase their market value at competitive rates off already high valuations? How will the biotech industry handle its public image--particularly as genomics becomes a consumer issue?